Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy.
O'Reilly MA, McHale C, Almazmi A, Hameed A, Benjamin D, O'Connell N, Murphy P, Quinn J, Thornton P, O'Gorman P, Frankova H, Sargent J, Verburgh E, McHugh J, Evans P, Enright H. O'Reilly MA, et al. Among authors: quinn j. Leuk Lymphoma. 2014 Dec;55(12):2950-1. doi: 10.3109/10428194.2014.904512. Epub 2014 Apr 22. Leuk Lymphoma. 2014. PMID: 24628297 No abstract available.
A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged over 85 years).
McDonald LS, McCarthy P, Khan M, Hogan P, Kelleher E, Murphy PT, Quinn J, Desmond R, McHugh J, Strickland M, O'Connell E, Cahill M, Maung SW, Keohane C, O'Neill D, Ryan D, Mykytiv V, Enright H. McDonald LS, et al. Among authors: quinn j. Leuk Lymphoma. 2019 May;60(5):1324-1327. doi: 10.1080/10428194.2018.1538513. Epub 2019 Jan 11. Leuk Lymphoma. 2019. PMID: 30632846 No abstract available.
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.
O'Dwyer M, Henderson R, Naicker SD, Cahill MR, Murphy P, Mykytiv V, Quinn J, McEllistrim C, Krawczyk J, Walsh J, Lenihan E, Kenny T, Hernando A, Hirakata G, Parker I, Kinsella E, Gannon G, Natoni A, Lynch K, Ryan AE. O'Dwyer M, et al. Among authors: quinn j. Blood Adv. 2019 Jun 25;3(12):1815-1825. doi: 10.1182/bloodadvances.2019000010. Blood Adv. 2019. PMID: 31201169 Free PMC article. Clinical Trial.
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
O'Gorman P, Laubach JP, O'Dwyer ME, Krawczyk J, Yee AJ, Gilligan O, Cahill MR, Rosenblatt J, Quinn J, Murphy PT, DiPietro H, Perera MR, Crotty GM, Cummings K, Hayden PJ, Browne P, Savell A, O'Leary HM, O'Keeffe D, Masone K, Hennessy BJ, Guerrero Garcia T, Scott K, Saeed K, Bianchi G, Dowling P, Tierney C, Richardson PG. O'Gorman P, et al. Among authors: quinn j. Am J Hematol. 2022 May;97(5):562-573. doi: 10.1002/ajh.26491. Epub 2022 Feb 18. Am J Hematol. 2022. PMID: 35132679 Free article. Clinical Trial.
Intracranial haemorrhage in AML patients.
Murphy P, Glavey S, Quinn J. Murphy P, et al. Among authors: quinn j. Eur J Haematol. 2022 Jun;108(6):536. doi: 10.1111/ejh.13761. Epub 2022 Mar 2. Eur J Haematol. 2022. PMID: 35202486 No abstract available.
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study.
Catherwood MA, Wren D, Chiecchio L, Cavalieri D, Donaldson D, Lawless S, ElHassadi E, Hayat A, Cahill MR, O'Shea D, Sargent J, Stewart P, Maurya M, Quinn J, Murphy P, de Castro DG, Mills K, Cross NCP, Forconi F, Iyengar S, Schuh A, Thornton P. Catherwood MA, et al. Among authors: quinn j. Front Oncol. 2022 Jun 28;12:909615. doi: 10.3389/fonc.2022.909615. eCollection 2022. Front Oncol. 2022. PMID: 35837095 Free PMC article.
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.
Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. Swan D, et al. Among authors: quinn j. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35985959 Clinical Trial.
3,174 results